SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Black Monday crash fears surrounding the 1987 anniversary and a recent tech-led pullback dominate discussion, while reports of rising futures fueled relief-rally and short-squeeze hopes. Traders remain divided between expecting a rebound and warning that selling could resume, with major-company earnings adding to market uncertainty.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for SELLAS to confirm the 80th overall-survival event in its blinded Phase 3 REGAL trial of GPS for AML dominates discussion, alongside a sharp share-price pullback and frustration with company silence. Bulls view the delayed trigger as a possible sign of extended patient survival, while bears question the trial design, disclosure timeline, and prospects for success; those interpretations remain speculative pending data.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO presentations on lifileucel are driving attention, especially the frontline melanoma combination data and sarcoma results. Traders debate whether the melanoma update adds meaningful new evidence or mainly confirms an older dataset, while many attribute the recent share-price weakness to a broader biotech selloff.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and semiconductor-led selloff has fueled concerns that AI spending and financing risks could pressure the broader market, with traders also fixated on Black Monday crash calls. The community is divided between expecting more downside and seeing an oversold rebound, with some dismissing the crash warnings and pointing to futures strength and upcoming big-tech earnings.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas Q3 earnings are the main focus, with traders weighing whether margins and cash flow can hold; the SpaceX-assisted Roadster reveal has added a polarizing side debate, with some praising the technology and others calling it a costly gimmick. Speculation about a TeslaSpaceX merger is also circulating, but no deal is confirmed.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERock is drawing attention as a potential provider of on-site natural-gas power for AI data centers, with traders focused on its Anthropic and Meta-related contracts and large backlog as evidence of demand. The community is largely bullish on growth and a possible short squeeze, but others are cautious about execution, the CEOs track record, and the stocks volatility.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys selloff is being tied mainly to MSCIs new index eligibility rules, which could lead to its removal from benchmarks and passive-fund selling; the final decision is still pending. Traders are split between expecting further pressure from potential outflows and viewing the risk as already priced in, while also watching Bitcoins direction and MSTRs sensitivity to it.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Rising crude prices amid conflict and supply-disruption fears around the Strait of Hormuz are lifting Chevron, which traders view as an oil-price proxy. The community is broadly bullish on the momentum and recent highs, though some caution that earnings will also depend on refining margins and that the stock may be overbought.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts withdrawal from the Nscale data-center lease in Essex, reportedly because grid power may not be available until the 2030s, is driving discussion. Traders debate whether it signals prudent capex discipline or broader weakness in AI infrastructure demand; others argue the issue is a local power constraint, not a pullback in demand.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos is drawing attention amid a steep slide to fresh 52-week lows despite reported contract wins, analyst upgrades, and strong defense-drone demand. Traders debate whether the weakness reflects valuation concerns, insider selling, and sector pressure or an oversold buying opportunity, with bulls adding shares as bears warn of further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich AtaxiaPR NewswireNEW YORK, Sept. 23, 2026 NEW YORK, Sept. 23, 2026...

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.read more...

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeut...

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple...

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...

Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...

Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2%  - Should You Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.64
Prev Close	$2.76
Open	$2.75
Dividend Yield	0.00%
50-Day Moving Average	$4.15
Beta	1.96
Avg. Volume	1.43M
PE Ratio	-2.28

52-Week High	$10.99
52-Week Low	$2.56
Market Capitalization	$216.71M
EPS (Annual)	-$1.86
Price to Book	0.88
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXEO Fundamentals